Randomised, Double-Blind, Single, 6 mg Fixed Dose, Two Treatment, Two-Period, Two-Sequence, Two-Way Crossover Comparative Pharmacokinetic and Pharmacodynamic (Phase I) Study of RGB-02 Compared to Neulasta in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacokinetics
- Sponsors Gedeon Richter
- 21 Nov 2017 Status changed from active, no longer recruiting to completed.
- 11 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 12 May 2017 New trial record